The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules

This is an analysis from a chemical point of view of the 46 drugs (34 New Chemical Entities and 12 Biologics) approved by the FDA during 2017. The drugs included in the 2017 “harvest” have been classified on the basis of their chemical structure: biologics (antibodies and proteins); peptides; amino...

Descripción completa

Detalles Bibliográficos
Autores principales: de la Torre, Beatriz G., Albericio, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017390/
https://www.ncbi.nlm.nih.gov/pubmed/29495494
http://dx.doi.org/10.3390/molecules23030533
_version_ 1783334738644172800
author de la Torre, Beatriz G.
Albericio, Fernando
author_facet de la Torre, Beatriz G.
Albericio, Fernando
author_sort de la Torre, Beatriz G.
collection PubMed
description This is an analysis from a chemical point of view of the 46 drugs (34 New Chemical Entities and 12 Biologics) approved by the FDA during 2017. The drugs included in the 2017 “harvest” have been classified on the basis of their chemical structure: biologics (antibodies and proteins); peptides; amino acids and natural products; drug combinations; and small molecules.
format Online
Article
Text
id pubmed-6017390
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60173902018-11-13 The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules de la Torre, Beatriz G. Albericio, Fernando Molecules Review This is an analysis from a chemical point of view of the 46 drugs (34 New Chemical Entities and 12 Biologics) approved by the FDA during 2017. The drugs included in the 2017 “harvest” have been classified on the basis of their chemical structure: biologics (antibodies and proteins); peptides; amino acids and natural products; drug combinations; and small molecules. MDPI 2018-02-27 /pmc/articles/PMC6017390/ /pubmed/29495494 http://dx.doi.org/10.3390/molecules23030533 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
de la Torre, Beatriz G.
Albericio, Fernando
The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules
title The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules
title_full The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules
title_fullStr The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules
title_full_unstemmed The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules
title_short The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules
title_sort pharmaceutical industry in 2017. an analysis of fda drug approvals from the perspective of molecules
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017390/
https://www.ncbi.nlm.nih.gov/pubmed/29495494
http://dx.doi.org/10.3390/molecules23030533
work_keys_str_mv AT delatorrebeatrizg thepharmaceuticalindustryin2017ananalysisoffdadrugapprovalsfromtheperspectiveofmolecules
AT albericiofernando thepharmaceuticalindustryin2017ananalysisoffdadrugapprovalsfromtheperspectiveofmolecules
AT delatorrebeatrizg pharmaceuticalindustryin2017ananalysisoffdadrugapprovalsfromtheperspectiveofmolecules
AT albericiofernando pharmaceuticalindustryin2017ananalysisoffdadrugapprovalsfromtheperspectiveofmolecules

Ejemplares similares